Literature DB >> 21459327

Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits.

Sofia Hult1, Rana Soylu1, Tomas Björklund2, Bengt F Belgardt3, Jan Mauer3, Jens C Brüning3, Deniz Kirik2, Åsa Petersén4.   

Abstract

In Huntington's disease (HD), the mutant huntingtin protein is ubiquitously expressed. The disease was considered to be limited to the basal ganglia, but recent studies have suggested a more widespread pathology involving hypothalamic dysfunction. Here we tested the hypothesis that expression of mutant huntingtin in the hypothalamus causes metabolic abnormalities. First, we showed that bacterial artificial chromosome-mediated transgenic HD (BACHD) mice developed impaired glucose metabolism and pronounced insulin and leptin resistance. Selective hypothalamic expression of a short fragment of mutant huntingtin using adeno-associated viral vectors was sufficient to recapitulate these metabolic disturbances. Finally, selective hypothalamic inactivation of the mutant gene prevented the development of the metabolic phenotype in BACHD mice. Our findings establish a causal link between mutant huntingtin expression in the hypothalamus and metabolic dysfunction, and indicate that metabolic parameters are powerful readouts to assess therapies aimed at correcting dysfunction in HD by silencing huntingtin expression in the brain.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21459327     DOI: 10.1016/j.cmet.2011.02.013

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  45 in total

1.  Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.

Authors:  Cesar L Moreno; Michelle E Ehrlich; Charles V Mobbs
Journal:  Neurobiol Dis       Date:  2015-10-17       Impact factor: 5.996

2.  Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.

Authors:  Brett D Dufour; Catherine A Smith; Randall L Clark; Timothy R Walker; Jodi L McBride
Journal:  Mol Ther       Date:  2014-01-06       Impact factor: 11.454

3.  Fat-free mass and its predictors in Huntington's disease.

Authors:  S D Süssmuth; V M Müller; C Geitner; G B Landwehrmeyer; S Iff; A Gemperli; Michael Orth
Journal:  J Neurol       Date:  2015-04-23       Impact factor: 4.849

4.  Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin.

Authors:  Elaine Waldron-Roby; Tamara Ratovitski; XiaoFang Wang; Mali Jiang; Erin Watkin; Nikolas Arbez; Rona K Graham; Michael R Hayden; Zhipeng Hou; Susumu Mori; Deborah Swing; Mikhail Pletnikov; Wenzhen Duan; Lino Tessarollo; Christopher A Ross
Journal:  J Neurosci       Date:  2012-01-04       Impact factor: 6.167

5.  Huntingtin-associated protein 1 regulates postnatal neurogenesis and neurotrophin receptor sorting.

Authors:  Jianxing Xiang; Hao Yang; Ting Zhao; Miao Sun; Xingshun Xu; Xin-Fu Zhou; Shi-Hua Li; Xiao-Jiang Li
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

6.  Systemic stress signalling: understanding the cell non-autonomous control of proteostasis.

Authors:  Rebecca C Taylor; Kristen M Berendzen; Andrew Dillin
Journal:  Nat Rev Mol Cell Biol       Date:  2014-03       Impact factor: 94.444

7.  Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions.

Authors:  Lydie Boussicault; Anne-Sophie Hérard; Noel Calingasan; Fanny Petit; Carole Malgorn; Nicolas Merienne; Caroline Jan; Marie-Claude Gaillard; Rodrigo Lerchundi; Luis F Barros; Carole Escartin; Thierry Delzescaux; Jean Mariani; Philippe Hantraye; M Flint Beal; Emmanuel Brouillet; Céline Véga; Gilles Bonvento
Journal:  J Cereb Blood Flow Metab       Date:  2014-06-18       Impact factor: 6.200

8.  Regulation of L-type Ca2+ Channel Activity and Insulin Secretion by Huntingtin-associated Protein 1.

Authors:  Jing-Ying Pan; Shijin Yuan; Tao Yu; Cong-Lin Su; Xiao-Long Liu; Jun He; He Li
Journal:  J Biol Chem       Date:  2016-09-13       Impact factor: 5.157

9.  Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.

Authors:  Jing Jin; Jennifer Albertz; Zhihong Guo; Qi Peng; Gay Rudow; Juan C Troncoso; Christopher A Ross; Wenzhen Duan
Journal:  J Neurochem       Date:  2013-03-05       Impact factor: 5.372

10.  A fully humanized transgenic mouse model of Huntington disease.

Authors:  Amber L Southwell; Simon C Warby; Jeffrey B Carroll; Crystal N Doty; Niels H Skotte; Weining Zhang; Erika B Villanueva; Vlad Kovalik; Yuanyun Xie; Mahmoud A Pouladi; Jennifer A Collins; X William Yang; Sonia Franciosi; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2012-09-21       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.